1207626-51-4

Basic information

• Product Name: 5-broMo-1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde
• Synonyms: 5-broMo-1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde;5-bromo-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine-3-carbaldehyde
• CAS NO: 1207626-51-4
• Molecular Formula: C₁₅H₁₁BrN₂O₃S
• Molecular Weight: 379.22844
• Mol File: 1207626-51-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-broMo-1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-broMo-1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde(1207626-51-4)
• EPA Substance Registry System: 5-broMo-1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde(1207626-51-4)

Safety Data

• Hazardous Substances Data: 1207626-51-4(Hazardous Substances Data)

Upstream product

• 757978-33-9 5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carboxaldehyde 
• 98-59-9 p-toluenesulfonyl chloride 
• 875639-15-9 5-bromo-3-iodo-1-(4-methylbenzene-1-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 757978-18-0 3-iodo-5-bromo-1H-pyrrolo[2,3-b]-pyridine 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1620574-93-7 (5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methanol 
• 1620574-95-9 5-bromo-3-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1111637-94-5 5-bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine 
• 1111637-95-6 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1620574-94-8 5-bromo-3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity

There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola. Adaptor-associated kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-associated host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses. Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells. Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analogue, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity. The optimized compounds demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus. These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7

The present invention relates to imidazolone derivatives of formula (I) to methods of preparing such derivatives, intermediates thereto, pharmaceutical compositions comprising such derivatives, and methods of inhibiting protein kinase, and methods of treatment comprising administration of such derivatives.